Fundraising FoxTransposon Therapeutics
San Diego, US · Founded 2019 · Delaware corporation · 2 known investors
Find your way into Transposon Therapeutics
Sign up to find every way you can get introduced to Transposon Therapeutics
- Your email: who you already know at Transposon Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Transposon Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Transposon Therapeutics is a biotechnology company developing therapies for neurodegenerative and aging-related diseases, with a pipeline that includes its lead candidate TPN-101 and novel NRTIs targeting conditions such as PSP, ALS/FTD, and Alzheimer's disease.
Founders & leadership
DP
Dennis PodlesakExecutive
LR
Lynne R. RollinsExecutive
EW
Eckard Weber, MDExecutive
Board
DH
Daniel Hetu, MD, MBABoard director
BA
WH
William Harrington, MD, MBABoard director
JP
KA
Keith A. KatkinBoard director
BT
Brian Taylor Slingsby, MD, PHD, MPHBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$59.1M disclosed across 4 rounds · 2020–2024
▶$4.7MraisedJul 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$4.7MraisedJul 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Keith A. KatkinDirector
- Dennis PodlesakExecutive Officer, Director
- Lynne R. RollinsExecutive Officer
- Daniel Hetu, MD, MBADirector
- Eckard Weber, MDExecutive Officer, Director
- Brent AhrensDirector
- Brian Taylor Slingsby, MD, PHD, MPHDirector
- William Harrington, MD, MBADirector
- John PacificoDirector
- Offering amount
- $20M
- Amount sold
- $4.7M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5MraisedJan 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$5MraisedJan 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Lynne R. RollinsExecutive Officer
- William Harrington, MD, MBADirector
- Brent AhrensDirector
- Daniel Hetu, MD, MBADirector
- Eckard Weber, MDExecutive Officer, Director
- Keith A. KatkinDirector
- Brian Taylor Slingsby, MD, PHD, MPHDirector
- John PacificoDirector
- Offering amount
- $20M
- Amount sold
- $5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$45.2MraisedDec 2020 · 10 investors · PharmaceuticalsRule 506(b)
▶$45.2MraisedDec 2020 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakExecutive Officer, Director
- Eckard Weber, M.D.Executive Officer, Director
- John PacificoDirector
- Brent AhrensDirector
- Lynne R. RollinsExecutive Officer
- Offering amount
- $45.2M
- Amount sold
- $45.2M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4.3MraisedMay 2020 · 4 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedMay 2020 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Eckard Weber, M.D.Executive Officer, Director
- Brent AhrensDirector
- John PacificoDirector
- Lynne RollinsExecutive Officer
- Offering amount
- $6.5M
- Amount sold
- $4.3M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Transposon Therapeutics.
Frequently asked questions
- What does Transposon Therapeutics do?
- Transposon Therapeutics is a biotechnology company developing therapies for neurodegenerative and aging-related diseases, with a pipeline that includes its lead candidate TPN-101 and novel NRTIs targeting conditions such as PSP, ALS/FTD, and Alzheimer's disease.
- Who are Transposon Therapeutics's investors?
- Transposon Therapeutics's investors include Canaan Partners, Lumira Ventures.
- How much funding has Transposon Therapeutics raised?
- Transposon Therapeutics has disclosed $59.1M raised across 4 rounds.
- Where is Transposon Therapeutics headquartered?
- Transposon Therapeutics is headquartered in San Diego, US.